MerLion Pharmaceuticals Pte Ltd
1 Science Park Road, #05-01 The Capricorn
Singapore Science Park
117528
Tel: 65-6829-5600
Fax: 65-6829-5601
Website: http://www.merlionpharma.com/
Email: enquiry@merlionpharma.com
11 articles about MerLion Pharmaceuticals Pte Ltd
-
MerLion Regains North American Rights to XTOROTM FDA-Approved Antibiotic for Treatment of Ear Infections
7/31/2018
MerLion Pharmaceuticals announced that Novartis has made a portfolio decision and terminated the license between Alcon (a subsidiary of Novartis) and MerLion executed in 2010 and returned all rights to MerLion. MerLion now owns all rights to XTORO™ globally.
-
MerLion Pharmaceuticals Pte Ltd To Present Detailed Phase 2 Data On Efficacy Of Finafloxacin In Complicated Urinary Tract Infections At International Congress Of Chemotherapy And Infection (ICC)
9/15/2015
-
MerLion Pharmaceuticals Pte Ltd Announces FDA Approval Of Finafloxacin Otic Suspension
2/11/2015
-
MerLion Pharmaceuticals Pte Ltd’s Finafloxacin Shows Positive Phase 2 Results In Complicated Urinary Tract Infections
1/9/2015
-
MerLion Pharmaceuticals Pte Ltd’s Finafloxacin Shows Positive Phase 2 Results In Complicated Urinary Tract Infections
1/8/2015
-
MerLion Pharmaceuticals Pte Ltd Completes Recruitment In Finafloxacin Phase II cUTI Trial
6/18/2014
-
MerLion Pharmaceuticals Pte Ltd Signs License Agreement with Alcon, Inc. to Develop and Commercialize Novel Finafloxacin Otic Product
1/11/2011
-
Merck & Co., Inc.'s (Jobs) Japanese Subsidiary Inks Oncology and Metabolic Drug Discovery Deal with MerLion Pharmaceuticals Pte Ltd
3/23/2007
-
MerLion Pharmaceuticals Pte Ltd And ICES Ink R&D Partnership To Boost Singapore'S Bio-Technology Industry
5/31/2006
-
MerLion Pharmaceuticals Pte Ltd Receives Frost & Sullivan Market Penetration Leadership Award
3/2/2006
-
MerLion Pharmaceuticals Pte Ltd Announces Sir Richard Sykes As New Chairman Of The Board Of Directors
2/14/2006